Article Versions Notes

Gruijs M, Ganzevles SH, Stigter-van Walsum M, van der Mast R, van Ostaijen-ten Dam MM, Tuk CW, Schilham MW, Leemans CR, Brakenhoff RH, van Egmond M, et al. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. International Journal of Molecular Sciences. 2021; 22(20):11057. https://doi.org/10.3390/ijms222011057

Gruijs, Mandy, Sonja H. Ganzevles, Marijke Stigter-van Walsum, Richard van der Mast, Monique M. van Ostaijen-ten Dam, Cornelis W. Tuk, Marco W. Schilham, C. René Leemans, Ruud H. Brakenhoff, Marjolein van Egmond, and et al. 2021. "NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models" International Journal of Molecular Sciences 22, no. 20: 11057. https://doi.org/10.3390/ijms222011057

Gruijs, M., Ganzevles, S. H., Stigter-van Walsum, M., van der Mast, R., van Ostaijen-ten Dam, M. M., Tuk, C. W., Schilham, M. W., Leemans, C. R., Brakenhoff, R. H., van Egmond, M., van de Ven, R., & Bakema, J. E. (2021). NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. International Journal of Molecular Sciences, 22(20), 11057. https://doi.org/10.3390/ijms222011057